Home >
Medicine Info >
Ixapana 20 mg Capsule
Loading interface...

Ixapana 20 mg Capsule

Manufactured byEMCURE PHARMACEUTICALS LTD
ContainsPanobinostat
Description
Ixapana 20 mg Capsule is an anticancer medicine which is used in combination with other medications to treat a type of blood cancer known as multiple myeloma in patients who have not adequately responded to other anticancer medications.
QUICK LINKS:
Side effectsConcernsUsageRelated products

Side effects

Major & minor side effects for Ixapana 20 mg Capsule

  • Decreased appetite
  • Stomach pain
  • Cough
  • Sleeplessnes
  • Dizziness
  • Headache
  • Nausea and vomiting
  • Severe diarrhea
  • Difficulty in breathing
  • Nose bleed
  • Indigestion
  • Weight loss
  • Redness of skin
  • Skin Rash
  • Chills

Uses of Ixapana 20 mg Capsule

What is it prescribed for?

  • Multiple Myeloma
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The amount of time required for this medicine to show its action is not clinically established.
  • How long do the effects of this medicine last?
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit-forming tendencies were reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.
  • Can this medicine be taken while breast-feeding?
    This medicine is recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

Allergy

This medicine is not recommended for use in patients with a known allergy to panobinostat or any other inactive ingredient present in the medicine.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.
General warnings

Driving or operating machinery

Use of this medicine may cause blurred vision or dizziness in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

Bonemarrow suppression

This medicine should be used with caution in patients having conditions like thrombocytopenia, agranulocytosis, anemia, or bone marrow suppression due to the increased risk of worsening of the patient's condition. A complete blood count should be performed before initiating treatment with this medicine. Close monitoring of blood counts is recommended during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Severe diarrhea

This medicine may cause severe diarrhea in some patients. Close monitoring of hydration status and blood electrolyte levels is recommended during treatment with this medicine. Appropriate corrective measures, dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Use in children

This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.

Risk of infections

Use of this medicine may weaken the immune system and may make you more vulnerable to infections. It is advised that you avoid coming in contact with people suffering from an infection while taking this medicine.

Internal bleeding or hemorrhage

This medicine should be used with caution due to the increased risk of internal bleeding or hemorrhages. Any symptoms such as unusual bleeding or bruising, black or tarry stools, vomiting up blood, etc. should be reported to the doctor on priority. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Missed Dose

The missed dose of this medicine should be taken within 12 hours after the scheduled dosing time. Do not double the dose to compensate for the missed dose.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Live attenuated vaccines and related products

Etanercept

Adalimumab

Clozapine

Warfarin

Aspirin

Disease interactions

Cardiac Diseases

This medicine should be used with caution in patients having a disease of the heart due to the increased risk of worsening of the patient's condition. Close monitoring of heart function is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Liver impairment

This medicine should be used with caution in patients with mild to moderate liver impairment due to the increased risk of severe adverse effects. Close monitoring of liver function is recommended for such patients during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition. This medicine is not recommended for use in patients with severe liver impairment.

Kidney impairment

This medicine should be used with extreme caution in patients suffering from kidney diseases due to the increased risk of worsening of the patient's condition. Close monitoring of kidney function is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.
Food interactions
Pomegranate, grapefruit or its juice may significantly increase the blood levels of this medicine. This may cause severe side effects such as nausea, vomiting, diarrhea, loss of appetite, mouth sores, hair loss, weakness, pain, numbness, etc. Hence, the consumption of pomegranate, grapefruit or its juice is not recommended during treatment with this medicine.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Carefully follow all the instructions given by your doctor. This medicine is given in multiple cycles. It is important to receive every scheduled dose and make a note of the next scheduled dose. Close monitoring of blood cell counts is necessary during treatment with this medicine. Ensure that the course of treatment is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

May cause sleepiness

How it works
This medicine works by inhibiting the growth and spread of cancer cells.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Antineoplastics, Histone deacetylase inhibitors

Schedule

Schedule H

Panobinostat - DrugBank [Internet]. Drugbank.ca. 2019 [cited 30 May 2019]. Available from:

https://www.drugbank.ca/drugs/DB06603

Faydak - Summary of Product Characteristics (SmPC) - (eMC) [Internet]. Medicines.org.uk. 2019 [cited 30 May 2019]. Available from:

https://www.medicines.org.uk/emc/product/7776/smpc

Panobinostat: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2019 [cited 30 May 2019]. Available from:

https://medlineplus.gov/druginfo/meds/a615020.html

[Internet]. Dailymed.nlm.nih.gov. 2019 [cited 30 May 2019]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7774972a-eeaa-4b9a-9e56-3fc1b968e86a
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 30 May 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.